Dydrogesterone, Estradiol | Femoston Conti tablets coated.pl.ob. 28 pcs.

release form

coated tablets coated

Packing

28 pcs

Indications

Hormone replacement therapy for disorders due to natural menopause or menopause, prevention of postmenopausal osteoporosis following surgery.

Contraindications

established or suspected pregnancy

period of lactation (breastfeeding)

diagnosed or suspected breast cancer with a history of

diagnosed or suspected estrogen-dependent malignant neoplastic diseases or blood vessels pulmonary thromboembolism)

active or recent arterial t rhomboembolism

acute liver disease, as well as a history of liver disease (before normalization of laboratory parameters of liver function)

untreated endometrial hyperplasia

porphyria

hypersensitivity to the drug.

Use with caution and under the supervision of a physician in patients receiving HRT and having the following conditions (currently or in history): uterine leiomyoma, endometriosis, thrombosis, and a history of their risk factors in the presence of risk factors for estrogen-dependent tumors (e.g. cancer of the patient’s mother), arterial hypertension, benign liver tumor, diabetes mellitus, cholelithiasis, epilepsy, migraine or intense headache, history of endometrial hyperplasia, systemic lupus erythematosus, bronchial asthma, renal failure, otosclerosis.

Use during pregnancy and lactation

The drug is contraindicated in pregnancy and lactation (breastfeeding).

If pregnancy occurs during treatment with Femoston, therapy should be stopped immediately.

Composition

1 tablet contains:

Active ingredients:

estradiol 1 mg,

dydrogesterone 5 mg

Excipients:

lactose monohydrate, srdlkldp OY-8734 orange: hypromellose, macrogol 400, titanium dioxide (E171), yellow iron oxide dye (E172), red iron oxide dye (E172).

Dosage and administration of

For the purpose of HRT and prevention of osteoporosis: by mouth, continuously, 1 tablet per day (preferably at the same time of day), regardless of food intake. The duration of therapy is determined by the ratio of the benefits and risks to women's health and the severity of estrogen deficiency.

Prevention of postmenopausal osteoporosis must be carried out taking into account the individual tolerance of the drug and possible effects on bone mass, which are dose-dependent.

Side effects of the

From the reproductive system: breast tenderness, breakthrough bleeding, pelvic pain are possible sometimes - changes in cervical erosion, changes in secretion, dysmenorrhea rarely - enlargement of the mammary glands, premenstrual-like syndrome in some cases - a change in libido.

From the digestive system: nausea, flatulence, abdominal pain are possible sometimes - cholecystitis is rare (0.01-0. 1%) - impaired liver function, in some cases accompanied by asthenia, malaise, jaundice or abdominal pain is very rare - vomiting.

From the side of the central nervous system: headache, migraine (1-10%) sometimes (0.1-1%) - dizziness, nervousness, depression are very rare - chorea.

From the cardiovascular system: sometimes - venous thromboembolism is very rare - myocardial infarction.

From the hemopoietic system: very rarely (less than 0.01%) - hemolytic anemia.

Dermatological reactions: sometimes - rash, itching very rarely - chloasma, melasma, erythema polymorphic, erythema nodosum, hemorrhagic purpura.

Allergic reactions: sometimes - urticaria in some cases - angioedema.

Other: change in body weight sometimes - vaginal candidiasis, breast carcinoma, an increase in the size of leiomyomas is rare - peripheral edema, intolerance to contact lenses, an increase in the curvature of the cornea in some cases (less than 0.01%) - exacerbation of porphyria.

Overdose

Symptoms: estradiol and dydrogesterone - substances with low toxicity.

No cases of overdose have been reported. Theoretically, in the case of overdose, symptoms such as nausea, vomiting, drowsiness, dizziness may occur.

Treatment: symptomatic.

Storage conditions

The drug should be stored at a temperature not exceeding 30 РC.

Shelf suitability

3 Year

Active ingredient

Dydrogesterone, Estradiol

Srdlp42 pharmacy distribution

Prescription

dosage form

dosage form

tablets